| Price | 220.00p on 30-01-2026 at 19:35:12 |
|---|---|
| Change | 1.00p 0.46% |
| Buy | 221.00p |
| Sell | 218.00p |
| Last Trade: | Buy 37.00 at 220.00p |
| Day's Volume: | 8,140 |
| Last Close: | 220.00p |
| Open: | 216.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 216.00p - 220.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.89b |
| VWAP: | 218.27136p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 37 | 220.00p | Suspected BUY Trade |
16:35:18 - 30-Jan-26 |
| Unknown* | 0 | 221.00p | SI Trade |
16:26:37 - 30-Jan-26 |
| Unknown* | 0 | 221.00p | SI Trade |
16:26:37 - 30-Jan-26 |
| Sell* | 171 | 218.00p | Automatic Execution |
16:26:37 - 30-Jan-26 |
| Sell* | 1 | 216.10p | Ordinary |
15:55:10 - 30-Jan-26 |
| Buy* | 64 | 219.50p | Ordinary |
15:14:15 - 30-Jan-26 |
| Buy* | 331 | 219.495p | Ordinary |
13:30:31 - 30-Jan-26 |
| Sell* | 2,000 | 216.149p | Ordinary |
11:41:38 - 30-Jan-26 |
| Buy* | 1 | 222.00p | SI Trade |
11:26:57 - 30-Jan-26 |
| Buy* | 4,555 | 219.50p | Ordinary |
09:49:47 - 30-Jan-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am | RNS | Blocklisting Six Monthly Return |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |
